Ronan Swords, MD., Ph.D., FRCPI, FRCPath

Ronan Swords, MD, Ph.D., FRCPI, FRCPath, is an Associate Professor of Medicine in the Division of Hematology/Medical Oncology at Oregon Health & Science University School of Medicine. His research focuses on developing novel pharmacotherapies for acute myeloid leukemia (AML) and other hematological malignancies, particularly targeting relapsed/refractory disease and older patient populations. His recent work includes phase Ib/II trials combining anti-CD33 monoclonal antibodies with azacitidine, evaluating ruxolitinib plus venetoclax, and investigating azacitidine, venetoclax, and revumenib in NPM1-mutated or KMT2A-rearranged AML. He also studies allogeneic transplant outcomes using post-transplant cyclophosphamide in elderly patients and leads the GEN-PHEN-VEN study correlating genetic and phenotypic factors with venetoclax responses.